Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$28.20 USD
+0.08 (0.28%)
Updated May 21, 2024 04:00 PM ET
After-Market: $28.20 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.20 USD
+0.08 (0.28%)
Updated May 21, 2024 04:00 PM ET
After-Market: $28.20 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
Zacks News
DexCom (DXCM) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results are likely to reflect rising volumes across all channels.
GE HealthCare (GEHC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance, driven by consistent NPIs and growing customer demand.
Cardinal Health (CAH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 16.67% and 1.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health (CAH) in Q2 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.
Cencora (COR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) first-quarter fiscal 2024 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
Revvity (RVTY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for its Life Sciences and Diagnostics franchises.
Henry Schein (HSIC) Up 4.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.
Dentsply (XRAY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Will Dentsply (XRAY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medical Product Stocks' Q3 Earnings Due on Nov 1: SYK & More
by Indrajit Bandyopadhyay
Third-quarter results of Medical Product companies are likely to reflect a year-over-year decline. Let's see how SYK, COR, BAX, FMS and XRAY fare this time around.
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Breast Health and GYN Surgical businesses will likely drive Hologic's (HOLX) Q4 revenues.
McKesson (MCK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) second-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Merit Medical (MMSI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 15.38% and 2.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued segmental strength.
Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
Dentsply International (XRAY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.
DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.
InMode (INMD) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
InMode (INMD) is likely to register growth in Q3, backed by strong consumable and service revenues and ongoing global expansion.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health (CVS) Q3 revenues will likely benefit from growth in specialty pharmacy and brand inflation and increased prescription and front store volume.
Will the Medicare Unit Aid Molina Healthcare's (MOH) Q3 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q3 results are expected to benefit on growing premiums and an expanding customer base within its Medicaid and Medicare businesses, partly offset by increased medical costs.